{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:31:50Z","timestamp":1790829110407,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,5]]},"DOI":"10.7759\/cureus.59695","type":"journal-article","created":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T22:32:59Z","timestamp":1714948379000},"source":"Crossref","is-referenced-by-count":3,"title":["Two Cases of Cardiovascular Adverse Events Following Subcutaneous Vosoritide Injection in Early Infancy"],"prefix":"10.7759","author":[{"given":"Atsushi","family":"Nishioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuho","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01623-w","article-title":"Vosoritide: first approval","volume":"81","author":"Duggan S","year":"2021","unstructured":"Duggan S. Vosoritide: first approval. Drugs. 2021, 81:2057-62. 10.1007\/s40265-021-01623-w","journal-title":"Drugs"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813446","article-title":"C-type natriuretic peptide analogue therapy in children with achondroplasia","volume":"381","author":"Savarirayan R","year":"2019","unstructured":"Savarirayan R, Irving M, Bacino CA, et al.. C-type natriuretic peptide analogue therapy in children with achondroplasia. N Engl J Med. 2019, 381:25-35. 10.1056\/NEJMoa1813446","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(23)00265-1","article-title":"Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"8","author":"Savarirayan R","year":"2024","unstructured":"Savarirayan R, Wilcox WR, Harmatz P, et al.. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Child Adolesc Health. 2024, 8:40-50. 10.1016\/S2352-4642(23)00265-1","journal-title":"Lancet Child Adolesc Health"},{"key":"ref4","unstructured":"European Medicines Agency. EU\/3\/12\/1094 - Orphan designation for treatment of achondroplasia. (2013). Accessed. April 9, 2024: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-12-1094."},{"key":"ref5","unstructured":"BioMarin Pharmaceutical Japan Inc.. VOXZOGO\u00ae dosing guide. (Article in Japanese). (2024). Accessed: April 9, 2024: https:\/\/www.bmrn.co.jp\/cms\/wp-content\/themes\/biomarin\/pdf\/physicians\/bmrn_voxzogo_04.pdf."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2018.04.004","article-title":"Assessing the accuracy of variant detection in cost-effective gene panel testing by next-generation sequencing","volume":"20","author":"Fujiki R","year":"2018","unstructured":"Fujiki R, Ikeda M, Yoshida A, et al.. Assessing the accuracy of variant detection in cost-effective gene panel testing by next-generation sequencing. J Mol Diagn. 2018, 20:572-82. 10.1016\/j.jmoldx.2018.04.004","journal-title":"J Mol Diagn"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01059-1","article-title":"Pharmacokinetics and exposure-response of vosoritide in children with achondroplasia","volume":"61","author":"Chan ML","year":"2022","unstructured":"Chan ML, Qi Y, Larimore K, et al.. Pharmacokinetics and exposure-response of vosoritide in children with achondroplasia. Clin Pharmacokinet. 2022, 61:263-80. 10.1007\/s40262-021-01059-1","journal-title":"Clin Pharmacokinet"},{"key":"ref8","unstructured":"BioMarin Pharmaceutical Inc. Voxzogo (vosoritide) for injection. Approved for children of all ages with achondroplasia and open growth plates. (2024). Accessed. April 9, 2024: https:\/\/www.voxzogo.com\/en-us\/."},{"key":"ref9","unstructured":"European Medicines Agency. Annex I. Summary of product characteristics. (2024). Accessed: April 9, 2024: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/voxzogo-epar-product-information_en.pdf."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.121.010573","article-title":"Orthostatic hypotension: management of a complex, but common, medical problem","volume":"15","author":"Fedorowski A","year":"2022","unstructured":"Fedorowski A, Ricci F, Hamrefors V, et al.. Orthostatic hypotension: management of a complex, but common, medical problem. Circ Arrhythm Electrophysiol. 2022, 15:e010573. 10.1161\/CIRCEP.121.010573","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00421-011-2194-7","article-title":"Pharmacokinetic analysis of absorption, distribution and disappearance of ingested water labeled with D\u2082O in humans","volume":"112","author":"P\u00e9ronnet F","year":"2012","unstructured":"P\u00e9ronnet F, Mignault D, du Souich P, Vergne S, Le Bellego L, Jimenez L, Rabasa-Lhoret R. Pharmacokinetic analysis of absorption, distribution and disappearance of ingested water labeled with D\u2082O in humans. Eur J Appl Physiol. 2012, 112:2213-22. 10.1007\/s00421-011-2194-7","journal-title":"Eur J Appl Physiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2044.1999.00660.x","article-title":"Safe pre-operative fasting times after milk or clear fluid in children. A preliminary study using real-time ultrasound","volume":"54","author":"Sethi AK","year":"1999","unstructured":"Sethi AK, Chatterji C, Bhargava SK, Narang P, Tyagi A. Safe pre-operative fasting times after milk or clear fluid in children. A preliminary study using real-time ultrasound. Anaesthesia. 1999, 54:51-9. 10.1046\/j.1365-2044.1999.00660.x","journal-title":"Anaesthesia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-015-0369-0","article-title":"Systematic review of the impact of feed protein type and degree of hydrolysis on gastric emptying in children","volume":"15","author":"Meyer R","year":"2015","unstructured":"Meyer R, Foong RX, Thapar N, Kritas S, Shah N. Systematic review of the impact of feed protein type and degree of hydrolysis on gastric emptying in children. BMC Gastroenterol. 2015, 15:137. 10.1186\/s12876-015-0369-0","journal-title":"BMC Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/EJA.0000000000001599","article-title":"Pre-operative fasting in children: a guideline from the European Society of Anaesthesiology and Intensive Care","volume":"39","author":"Frykholm P","year":"2022","unstructured":"Frykholm P, Disma N, Andersson H, et al.. Pre-operative fasting in children: a guideline from the European Society of Anaesthesiology and Intensive Care. Eur J Anaesthesiol. 2022, 39:4-25. 10.1097\/EJA.0000000000001599","journal-title":"Eur J Anaesthesiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/anae.14892","article-title":"An international multidisciplinary consensus statement on fasting before procedural sedation in adults and children","volume":"75","author":"Green SM","year":"2020","unstructured":"Green SM, Leroy PL, Roback MG, et al.. An international multidisciplinary consensus statement on fasting before procedural sedation in adults and children. Anaesthesia. 2020, 75:374-85. 10.1111\/anae.14892","journal-title":"Anaesthesia"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/250126-two-cases-of-cardiovascular-adverse-events-following-subcutaneous-vosoritide-injection-in-early-infancy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T22:33:03Z","timestamp":1714948383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/250126-two-cases-of-cardiovascular-adverse-events-following-subcutaneous-vosoritide-injection-in-early-infancy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,5]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.59695","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,5]]}}}